A patient with bilateral pneumonia is positioned for drainag…
A patient with bilateral pneumonia is positioned for drainage of the lateral and medial segments of her right middle lobe. Afer 5 min. in this position, the patient complains of SOB. The EKG shows the patient to be having premature ventricular contractions (PVCs). The most likely cause of this is
Read DetailsA 75-year-old man comes to your clinic with complaints of ri…
A 75-year-old man comes to your clinic with complaints of right hip pain and dysfunction. He notes that this has been coming on for some time, but has worsened significantly over the past 6 weeks. He notes he seems to be losing strength in his right leg. He reports mild numbness at his big toe. He is an avid hunter, but is now unable to climb trees to get to his tree stand. The patient’s referral from the sports MD gave a diagnosis of hip arthritis due to imaging findings of mild joint space loss. You don’t feel that this is likely and want to rule out this diagnosis. Tests with high______are used for screening purposes because a negative test would rule____this pathology.
Read DetailsThe patient is a 29-year-old male with a two-week history of…
The patient is a 29-year-old male with a two-week history of right calf pain. He reports increased calf pain with prolonged sitting and with lumbar flexion in standing, and decreased calf pain—with increased low back pain—during repeated lumbar extension in standing and prone. A straight-leg raise is positive on the right. You have prescribed the exercise shown in the attached image, instructing the patient to repeatedly bend and straighten his elbows to extend the lumbar spine and then return to lying flat. Based on this presentation, which additional intervention is MOST likely indicated for his plan of care?
Read DetailsPlease read this abstract from a clinical trial: Randomised…
Please read this abstract from a clinical trial: Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) Background: To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC). Methods: Patients were randomised to receive either FOLFIRI plus Bev 5 mg/kg every 2 weeks (Arm-A) or CAPIRI plus Bev 7.5 mg/kg every 3 weeks (Arm-B). Results: Three hundred thirty-three patients (Arm-A=167; Arm-B=166) were enrolled into the study. No difference was observed in median progression-free survival (PFS) (10.0 and 8.9 months; P=0.64), overall survival (25.7 and 27.5 months; P=0.55) or response rates (45.5 and 39.7%; P=0.32) for FOLFIRI-Bev and CAPIRI-Bev, respectively. Patients treated with CAPIRI-Bev presented significantly higher incidence of diarrhoea (P=0.005), febrile neutropenia (P=0.003) and hand-foot skin reactions (P=0.02) compared with patients treated with FOLFIRI-Bev. Treatment delays (P=0.05), dose reduction (P
Read Details